Drugs / Immunose FLU
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03437304 | Feb → Jun 2018 | influenza | Eurocine Vaccines AB | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immunose FLU | “A second dose of Immunose FLU 2% will be administered 3 weeks later.” NCT03437304 ↗ |
| Modality | Vaccine | “Quadrivalent influenza vaccine with 30 μg HA/strain and 1% Endocine™” NCT03437304 ↗ |
| Route | Intranasal | “intranasal administration” NCT03437304 ↗ |